These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 624843)

  • 1. Complement receptors: specific detection by molecular complexes.
    Cossman J; Glorioso JC; Adler R
    J Immunol Methods; 1978; 19(2-3):227-34. PubMed ID: 624843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin-mediated shifting of immune complexes to increased complement-dependent solubility and immunoadherence.
    Spycher MO; Späth PJ; Häsig A; Nydegger UE
    Mol Immunol; 1984 Jun; 21(6):497-505. PubMed ID: 6431266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding to erythrocyte complement receptor type 1 of BSA/anti-BSA complexes opsonized by C4A3 or C4B1 in the presence of serum.
    Klint C; Truedsson L; Sturfelt G
    Scand J Immunol; 1995 Oct; 42(4):425-32. PubMed ID: 7569775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanism of solubilization of immune precipitates by serum.
    Czop J; Nussenzweig V
    J Exp Med; 1976 Mar; 143(3):615-30. PubMed ID: 1249522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the alternative complement pathway by the immune precipitate formed with F(ab')2 fragment of human IgG antibody.
    Akagaki Y; Inai S
    Mol Immunol; 1983 Nov; 20(11):1221-6. PubMed ID: 6419059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activation of C3 and C4 in human serum by immune complexes containing mouse monoclonal antibodies of different isotype and affinity: effects on solubilisation.
    Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
    Mol Immunol; 1988 Dec; 25(12):1355-61. PubMed ID: 3266294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
    Miletic VD; Hester CG; Frank MM
    J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems in the detection of complement-fixing immune complexes.
    Rødahl E
    Acta Pathol Microbiol Immunol Scand C; 1985 Jun; 93(3):125-30. PubMed ID: 3875968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new complement function: solubilization of antigen-antibody aggregates.
    Miller GW; Nussenzweig V
    Proc Natl Acad Sci U S A; 1975 Feb; 72(2):418-22. PubMed ID: 1054824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of immune precipitation by complement.
    Schifferli JA; Bartolotti SR; Peters DK
    Clin Exp Immunol; 1980 Nov; 42(2):387-94. PubMed ID: 6781802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.
    Theofilopoulos AN; Dixon FJ; Bokisch VA
    J Exp Med; 1974 Oct; 140(4):877-94. PubMed ID: 4139225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating immune complexes with polyethylene glycol precipitation F(ab')2 anti-C3 ELISA.
    Xu RJ; Gu YA
    J Immunol Methods; 1990 Dec; 135(1-2):225-31. PubMed ID: 2273258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakdown of C3 covalently bound to F(ab')2 immune complexes after complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Marqués G; Sánchez-Corral P; Vivanco F
    Complement; 1986; 3(2):53-62. PubMed ID: 3769463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of complement amplification by F(ab')(2)-containing immune complexes and naturally occurring anti-hinge antibodies, possible role in systemic inflammation.
    Lutz HU; Fumia S
    Autoimmun Rev; 2008 Jun; 7(6):508-13. PubMed ID: 18558371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
    Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the preparation of F(ab')2 antibody from soluble immune complexes to determine the complexed antigens.
    Dambuyant C; Burton-Kee J; Mowbray JF
    J Immunol Methods; 1978; 24(1-2):31-8. PubMed ID: 363951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.